Guided Therapeutics (GTHP) Cost of Revenue (2012 - 2025)
Guided Therapeutics (GTHP) reported Cost of Revenue of $132000.0 for Q4 2025, up 4300.0% on a YoY basis from $3000.0 in Q4 2024, and up 428.0% sequentially from $25000.0 in Q3 2025.
Guided Therapeutics (GTHP) Cost of Revenue (2012 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 14 years of Cost of Revenue data on file, last reported at $132000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue rose 4300.0% year-over-year to $132000.0; the trailing twelve-month figure through Dec 2025 stood at $195000.0 (up 3800.0% YoY), and the FY2025 full-year result was $196000.0, up 3820.0% from the prior year.
- Cost of Revenue rose to $132000.0 in Q4 2025, from $25000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $132000.0 in Q4 2025 to a low of $1000.0 in Q1 2022.
- A 5-year average of $28857.1 and a median of $17500.0 in 2021 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue plunged 81.25% in 2024 and soared 4300.0% in 2025, its largest moves.
- Tracing GTHP's Cost of Revenue over 5 years: stood at $19000.0 in 2021, then jumped by 315.79% to $79000.0 in 2022, then plunged by 79.75% to $16000.0 in 2023, then sank by 81.25% to $3000.0 in 2024, then soared by 4300.0% to $132000.0 in 2025.
- Business Quant data shows GTHP's Cost of Revenue at $132000.0 in Q4 2025, $25000.0 in Q3 2025, and $38000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.89 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.21 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 3.40 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 12.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 362.60 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 441.60 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 481.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 2.51 Bn |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | 132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 132,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 79,000.00 |
| Dec 31, 2022 | 79,000.00 |